Onco-Carbide
Brand names,
Onco-Carbide
Analogs
Onco-Carbide
Brand Names Mixture
Onco-Carbide
Chemical_Formula
CH4N2O2
Onco-Carbide
RX_link
http://www.rxlist.com/cgi/generic2/hydroxyurea.htm
Onco-Carbide
fda sheet
Onco-Carbide
msds (material safety sheet)
Onco-Carbide
Synthesis Reference
No information avaliable
Onco-Carbide
Molecular Weight
76.0547 g/mol
Onco-Carbide
Melting Point
142-146 oC
Onco-Carbide
H2O Solubility
1E+006 mg/L
Onco-Carbide
State
Solid
Onco-Carbide
LogP
-1.432
Onco-Carbide
Dosage Forms
Capsule
Onco-Carbide
Indication
For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Onco-Carbide
Pharmacology
Hydroxyurea has dose-dependent synergistic activity with cisplatin in vitro. In vivo Hydroxyurea showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Hydroxyurea was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to Hydroxyurea 4 hours before cisplatin produced the greatest interaction.
Onco-Carbide
Absorption
Well absorbed from the gastrointestinal tract.
Onco-Carbide
side effects and Toxicity
Oral, mouse: LD50 = 7330 mg/kg; Oral, rat: LD50 = 5760 mg/kg
Onco-Carbide
Patient Information
HYDREA is a medication that must be handled with care. People who are not taking HYDREA should not be
exposed to it. If the powder from the capsule is spilled, it should be wiped up immediately with a damp disposable
towel and discarded in a closed container, such as a plastic bag. The medication should be kept away from children
and pets.
Onco-Carbide
Organisms Affected
Humans and other mammals